SCHEMBL1024276

SCHEMBL1024276

Cc1cc2cn[nH]c2cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.53
MAPT P10636 3/20 0.53
CYP3A4 P08684 2/20 0.53
LMNA P02545 1/20 0.53
ALOX15 P16050 1/20 0.53
POLB P06746 1/20 0.53
MAOB P27338 1/20 0.53
HSF1 Q00613 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
APEX1 P27695 1/20 0.45
NOS3 P29474 1/20 0.45
CYP2C19 P33261 1/20 0.45
NOS2 P35228 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680531 0.95 NOS1 (0.54) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL1026662 0.95 NOS1 (0.54) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL1744194 0.90 CHEK1 (0.45) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL11680975 0.86 MAPT (0.59) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL616791 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL31717179 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL28067945 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL27228526 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL28629877 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL17373905 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224759-A1 INDANOL SUBSTITUTED DIAMINO PYRIMIDINE CARBOXAMIDES AS DUAL ATM/DNA-PK INHIBITORS BUGWORKS RESEARCH INDIA PVT. LTD (IN) 2025-10-30 WO disclosed
WO-2024158872-A1 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF THE ROCKEFELLER UNIVERSITY (US) 2024-08-02 WO disclosed
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 WO disclosed
US-20220194939-A1 Novel compounds and methods of use treating fructose-related disorders or diseases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-23 US disclosed
EP-3955914-A1 NOVEL COMPOUNDS AND METHODS OF USE TREATING FRUCTOSE-RELATED DISORDERS OR DISEASES Colorado Research Partners, LLC (US) 2022-02-23 EP disclosed
CN-114007602-A Novel compounds and methods of use for treating fructose-related disorders or diseases 科罗拉多研究合作伙伴有限责任公司 2022-02-01 CN disclosed
CN-110546150-B Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof 江苏豪森药业集团有限公司 2021-12-21 CN disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
EP-1987028-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS Transtech Pharma, Inc. (US) 2008-11-05 EP disclosed
US-7273863-B1 Benzophenones as inhibitors of reverse transcriptase SMITHKLINE BEECHAM CORPORATION (US) 2007-09-25 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed
WO-2007095124-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2007-08-23 WO disclosed
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed
US-4352931-A Lin-benzoaminopurinols SIEGFRIED AKTIENGESELLSCHAFT (CH) 1982-10-05 US disclosed
EP-0040872-A1 Pyrazolo-quinazoline derivatives and methods of producing such derivatives SIEGFRIED AKTIENGESELLSCHAFT (CH) 1981-12-02 EP disclosed
US-4223143-A PYRAZOLO-QUINAZOLIN-ONES, CONTROLLING URIC ACID CONCENTRATION, GOUT, XANTHINE OXIDASE SIEGFRIED AKTIENGESELLSCHAFT (CH) 1980-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 NOS1 554/4885MAPT 3727/4885CYP3A4 194/4885
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 NOS1 236/4885MAPT 2429/4885CYP3A4 83/4885
US-20220194939-A1 Novel compounds and methods of use treating fructose-related disorders or diseases GCK, KHK, HK1 NOS1 3020/4885MAPT 1208/4885CYP3A4 2057/4885
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 NOS1 4272/4885MAPT 623/4885CYP3A4 4689/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB NOS1 3629/4885MAPT 1464/4885CYP3A4 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.